Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer
Oxurion NV appoints Tom Graney, CFA as
Chief Financial Officer
Boston-based former Vertex and Generation
Bio CFO Brings Significant Operational, US Capital Markets
and Investor Relations Expertise
Leuven, Belgium and Boston, MA, USA;
13th October 2020 – 5.45 p.m. CET – Oxurion NV (Euronext
Brussels: OXUR), a biopharmaceutical company developing next
generation standard-of-care therapies for Diabetic Macular Edema
(DME), is pleased to announce the appointment of Tom Graney as its
Chief Financial Officer (CFO). Mr. Graney will begin his role on
14th October and will be based in Boston, MA, US. He will succeed
Dominique Vanfleteren who, according to plan, is leaving Oxurion to
pursue other interests.
Mr. Graney will be responsible for the extension
and execution of the financial strategy to support Oxurion's
ambitious global growth plans, including the important US
market.
Tom has over 25 years’ experience in senior
finance, strategy and operational roles including capital raising,
accounting, and audit. He most recently served as CFO at
Generation Bio (NASDAQ: GBIO), a non-viral gene therapy company
based in Cambridge, MA, where he led all of the company’s financial
operations.
Prior to joining Generation Bio, Tom was Senior
Vice President (SVP) and CFO at Vertex Pharmaceuticals (NASDAQ:
VRTX), one of the world’s most highly valued biotech companies,
with a multi-billion-dollar turnover. At Vertex Tom was responsible
for financial strategy and operations including finance,
accounting, and internal audit functions.
Prior to Vertex, he was the CFO and SVP of
Finance and Corporate Strategy at Ironwood Pharmaceuticals (NASDAQ:
IRWD), a GI-focused healthcare company. Before joining Ironwood,
Tom spent 20 years with Johnson & Johnson, serving in various
roles in the US and abroad, including being Worldwide VP of Finance
and CFO of Ethicon, a major medical device company, and VP and CFO
of Janssen Pharmaceuticals NA, a major pharmaceutical company in
North America.
Tom is currently on the board of AC Immune SA
(NASDAQ: ACIU), a clinical stage Swiss biopharmaceutical company
focused on neurodegenerative diseases.
Tom holds a Bachelor of Science degree in
accounting from the University of Delaware and a Master of Business
Administration in marketing, finance, and international business
from the Leonard N. Stern School of Business at New York
University. Tom is also a CFA charterholder.
“We are delighted to welcome Tom to Oxurion. I
am convinced that Tom’s significant financial management and US
capital markets experience will enable him to play a crucial role
in the successful execution of our plans to develop the industry
leading franchise for the treatment of DME, currently a $4.5
billion annual market opportunity. With both Tom and Grace, our
recently appointed CMO, being based in the US, we are starting to
build the transatlantic organization we need to deliver on our
global ambition.
On behalf of the Board I would like to take this
opportunity to thank Dominique for his contribution to Oxurion over
the last 5 years and for agreeing to support us to ensure a smooth
transition. I would like to wish him every success in his future
career.” said Dr Patrik De Haes, CEO of
Oxurion.
Tom Graney, the newly appointed CFO of
Oxurion, added: “I am excited to have the opportunity to
work with Patrik and the team at Oxurion. With THR-149 and THR-687,
I believe Oxurion has two highly differentiated new drug candidates
that have the potential to address the needs of nearly all patients
with DME, a serious sight threatening condition. I am looking
forward to using my experience to ensure Oxurion has continued
access to the financial resources needed to achieve its ambitious
corporate goals.”
_
Oxurion Virtual R&D Investor Day to take
place on Thursday 15th October 2020 at 5.30 p.m. CET/ 11.30 a.m.
ET
Please consult Oxurion’s website for registration and call
details, or follow this
link:https://www.investis-live.com/oxurion/5f7c2e6ed33b270c005a4f88/ffdl
END
For further information please contact:
Oxurion NVDr Patrik De HaesCEOTel: +32 16 75 13 10 |
Citigate Dewe Rogerson David Dible/ Sylvie Berrebi/ Frazer HallTel:
+44 20 7638 9571oxurion@citigatedewerogerson.com |
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to better preserve
vision in patients with diabetic macular edema (DME), the leading
cause of vision loss in diabetic patients worldwide.
Oxurion is building a leading global franchise
in the treatment of DME, based on the successful development of its
two novel therapeutics:
·THR-149, a plasma kallikrein inhibitor
being developed as a potential new standard of care for DME
patients who respond sub-optimally to anti-VEGF therapy.
THR-149 has shown positive topline Phase 1
results for the treatment of DME. The Company is currently
conducting a Phase 2 clinical trial evaluating THR-149 with
DME-patients who previously responded sub-optimally to anti-VEGF
therapy.
THR-149 was developed in conjunction with
Bicycle Therapeutics PLC (NASDAQ: BCYC).
·THR-687, is a pan-RGD integrin inhibitor,
that is initially being developed as a potential new standard of
care for all DME patients.
Positive topline results in a Phase 1 clinical
study assessing THR-687 as a treatment for DME were announced in
January 2020. THR-687 is expected to enter a Phase 2 clinical trial
by mid-2021.
THR-687 is an optimized compound derived from a
broader library of integrin inhibitors in-licensed from Galapagos
NV (Euronext & NASDAQ: GLPG).
Oxurion is headquartered in Leuven, Belgium, and is listed on
the Euronext Brussels exchange under the symbol OXUR.
More information is available at
www.oxurion.com.
Important information about
forward-looking statementsCertain statements in this press
release may be considered “forward-looking”. Such forward-looking
statements are based on current expectations, and, accordingly,
entail and are influenced by various risks and uncertainties. The
Company therefore cannot provide any assurance that such
forward-looking statements will materialize and does not assume an
obligation to update or revise any forward-looking statement,
whether as a result of new information, future events, or any other
reason. Additional information concerning risks and uncertainties
affecting the business and other factors that could cause actual
results to differ materially from any forward-looking statement is
contained in the Company’s Annual Report. This press release does
not constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No
securities of Oxurion may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933,
as amended, or in compliance with an exemption therefrom, and in
accordance with any applicable U.S. state securities laws.
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Apr 2023 a Apr 2024